Literature DB >> 33037471

Surface Composition and Aerosolization Stability of an Inhalable Combinational Powder Formulation Spray Dried Using a Three-Fluid Nozzle.

Nivedita Shetty1,2, Yiwen Zhang1, Heejun Park1, Dmitry Zemlyanov3, Dishan Shah1, Athena He1, Patricia Ahn1, Tarun Tejasvi Mutukuri1, Hak-Kim Chan4, Qi Tony Zhou5.   

Abstract

PURPOSE: This study aims to understand the impact of spray drying nozzles on particle surface composition and aerosol stability.
METHODS: The combination formulations of colistin and azithromycin were formulated by 2-fluid nozzle (2 N) or 3-fluid (3 N) spray drying in a molar ratio of 1:1. A 3-factor, 2-level (23) factorial design was selected to investigate effects of flow rate, inlet temperature and feed concentration on yield of spray drying and the performance of the spray dried formulations for the 3 N.
RESULTS: FPF values for the 2 N formulation (72.9 ± 1.9% for azithromycin & 73.4 ± 0.8% for colistin) were higher than those for the 3 N formulation (56.5 ± 3.8% for azithromycin & 55.1 ± 1.6% for colistin) when stored at 20% RH for 1 day, which could be attributed to smaller physical size for the 2 N. There was no change in FPF for both drugs in the 2 N formulation after storage at 75% RH for 90 days; however, there was a slight increase in FPF for colistin in the 3 N formulation at the same storage conditions. Surface enrichment of hydrophobic azithromycin was measured by X-ray photoelectron spectroscopy for both 2 N and 3 N formulations and interactions were studied using FTIR.
CONCLUSIONS: The 3-fluid nozzle provides flexibility in choosing different solvents and has the capability to spray dry at higher feed solid concentrations. This study highlights the impact of hydrophobic azithromycin enrichment on particle surface irrespective of the nozzle type, on the prevention of moisture-induced deterioration of FPF for hygroscopic colistin.

Entities:  

Keywords:  aerosol performance; dry powder inhaler; spray drying; surface composition; three-fluid nozzle

Mesh:

Substances:

Year:  2020        PMID: 33037471      PMCID: PMC7647382          DOI: 10.1007/s11095-020-02937-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  34 in total

Review 1.  Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections.

Authors:  Jian Li; Roger L Nation; John D Turnidge; Robert W Milne; Kingsley Coulthard; Craig R Rayner; David L Paterson
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

2.  Preparation of sustained-release coated particles by novel microencapsulation method using three-fluid nozzle spray drying technique.

Authors:  Keita Kondo; Toshiyuki Niwa; Kazumi Danjo
Journal:  Eur J Pharm Sci       Date:  2013-09-12       Impact factor: 4.384

3.  Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Yang Hu; Nikolas J Onufrak; Siping Sun; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

4.  Nanoscale investigation of the interaction of colistin with model phospholipid membranes by Langmuir technique, and combined infrared and force spectroscopies.

Authors:  Oona Freudenthal; Fabienne Quilès; Grégory Francius; Kamila Wojszko; Marcelina Gorczyca; Beata Korchowiec; Ewa Rogalska
Journal:  Biochim Biophys Acta       Date:  2016-07-30

5.  Physico-Chemical Properties, Aerosolization and Dissolution of Co-Spray Dried Azithromycin Particles with L-Leucine for Inhalation.

Authors:  Sharad Mangal; Haichen Nie; Rongkun Xu; Rui Guo; Alex Cavallaro; Dmitry Zemlyanov; Qi Tony Zhou
Journal:  Pharm Res       Date:  2018-01-08       Impact factor: 4.200

6.  Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center.

Authors:  Joshua D Hartzell; Robert Neff; Julie Ake; Robin Howard; Stephen Olson; Kristopher Paolino; Mark Vishnepolsky; Amy Weintrob; Glenn Wortmann
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

Review 7.  Inhaled colistin for lower respiratory tract infections.

Authors:  Sabina Antonela Antoniu; Ileana Cojocaru
Journal:  Expert Opin Drug Deliv       Date:  2012-02-14       Impact factor: 6.648

8.  Use of parenteral colistin for the treatment of serious infection due to antimicrobial-resistant Pseudomonas aeruginosa.

Authors:  Peter K Linden; Shimon Kusne; Kim Coley; Paulo Fontes; David J Kramer; David Paterson
Journal:  Clin Infect Dis       Date:  2003-10-29       Impact factor: 9.079

9.  Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

10.  Nebulized Colistin And Continuous Cyclic Azithromycin In Severe COPD Patients With Chronic Bronchial Infection Due To Pseudomonas aeruginosa: A Retrospective Cohort Study.

Authors:  Concepción Montón; Elena Prina; Xavier Pomares; Jose R Cugat; Antonio Casabella; Joan Carles Oliva; Miguel Gallego; Eduard Monsó
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-10-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.